Launch of Juno, MedPal's AI Health Companion
18 June 2026
MedPal AI plc
("MedPal AI") or the "Company")
Launch of "Juno": MedPal AI's Agentic AI Health Companion
MedPal AI moves from responsive AI to agentic AI, powered by Anthropic's latest Claude models and DigitalOcean
MedPal AI plc, the AI-native digital health and pharmacy group, is pleased to announce the launch of "Juno", its next-generation agentic AI health companion, alongside a full upgrade of the technology that powers it.
Juno represents a step change: from AI that answers when asked, to AI that works on the patient's behalf. Rather than waiting for a question, Juno proactively watches over a patient's health information through MedPal AI's New Health OS Portal and reaches out directly, by text over WhatsApp and the web.
As part of the upgrade, MedPal AI has migrated its entire AI stack away from Google Vertex AI to a new multi-layer architecture. Anthropic's latest Claude models now drive Juno's agentic reasoning and conversation, while clinical response layers run on dedicated DigitalOcean infrastructure. The result is a faster, more capable and more autonomous health agent.
The launch lands squarely in what the market has called the "OpenClaw moment": the shift, seen across consumer technology in 2026, to agentic assistants that understand natural text and voice and actively manage tasks for the user, rather than simply replying to prompts. Juno brings that same paradigm to healthcare.
Consumer demand for AI-led health support has reached record levels. OpenAI reports that more than 40 million people now turn to ChatGPT every day with health-related questions. But general-purpose chatbots stop at information: they can describe a problem; they cannot resolve it.
Juno is built to close that gap, and to close the loop. Trained by MedPal AI's own clinical services team, Juno provides advice and triage and, where clinically appropriate, connects the patient to one of MedPal AI's GPs, who can prescribe as appropriate. Medication is then dispensed through the Company's robotic dispensing infrastructure directly to the patient's door, with Juno following up to check on outcomes. The result is a single, continuous pathway from first question to resolved outcome. Put simply, New Health does not just tell you what the problem is, it helps to treat it.
Patients can talk to Juno today on WhatsApp at 07300 100 700, or on the web at new.co.uk.
Jason Drummond, Founder and Chief Executive of MedPal AI, commented:
"The world has just watched agentic AI go mainstream, and tens of millions of people are already asking AI about their health every single day. The difference with Juno is that it does not stop at an answer. It can advise, triage, connect you to one of our GPs, have your medication dispensed by robot and shipped to your door, and then check that you are getting better. That is the whole point of Health OS. We do not just tell you what is wrong, we help to treat it."
This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014 (which forms part of domestic UK law pursuant to the European Union (Withdrawal) Act 2018). The Directors of the Company are responsible for the contents of this announcement
Enquiries:
MedPal AI plc
Jason Drummond, Chief Executive Officer
Via Square1 Consulting
Cairn Financial Advisers LLP
Louise O'Driscoll/Jo Turner
+44 (0) 20 7213 0880
Oak Securities (a trading name of Merlin Partners LLP)
Tim Dainton/Calvin Man
+44 (0) 20 3973 3678
Clear Capital Markets Limited
Bob Roberts
+44 (0) 20 3869 6080
Square1 Consulting
David Bick
+44 (0) 20 7929 5599
+44 (0) 7831 381201
About MedPal AI
MedPal AI is a UK-based digital health company building the MedPal Health OS - a vertically integrated, closed-loop platform spanning AI wellness, clinical services, and automated pharmacy fulfilment. Its core app aggregates data from over 100 wearable devices and health apps (including Apple Health, Fitbit, Garmin, and Whoop) into a unified health profile, offering personalised, non-clinical lifestyle guidance through its AI wellness coach and acting as the consumer front door to the Company's clinical and pharmacy services.
Through its wholly owned subsidiary MedPal Limited, the Company operates a 24/7 AI-powered automated pharmacy distribution centre, providing nationwide NHS and private prescription services. The facility leverages BD Rowa VMAX robotic dispensing technology integrated with AI triage to deliver rapid, cost-effective medication fulfilment with same-day and next-day delivery capabilities.
MedPal AI has a partnership agreement with Epassi UK Limited, which will, for a limited time, grant exclusive, zero-cost access to the MedPal AI app across Epassi's network of 11M+ employees at major firms. The Company's LEI is 984500EDP8B0A14CBA61.
Forward Looking Statements
This announcement contains forward-looking statements, which are based on the Company's current expectations, intentions and projections regarding its future performance, anticipated events or trends and other matters that are not historical facts. Forward-looking statements are often identified by words such as "believes", "expects", "intends", "may", "will", "should", "could", "plans", "targets", "aims" or similar expressions. Such statements are subject to risks, assumptions and uncertainties and actual results, performance or events may differ materially from those expressed or implied by them. The Company undertakes no obligation to update any forward-looking statements, except as required by applicable law, the AIM Rules for Companies, the UK Market Abuse Regulation or other applicable regulation.
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.ENDSTRGZGMVVNDGVZM
